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ABSTRACT
Neuromedin U (NmU) -a neuropeptide belonging to the neuromedin family– plays a substantial role in
HER2-positive breast cancer, correlating with increased aggressiveness, resistance to HER2-targeted
therapies and overall signiﬁcantly poorer outcome for patients. However, the mechanism through which it
exerts these effects remains unclear. To elucidate this, initially we used HER2-positive breast cancer cells
stably over-expressing NmU. These cells and their released extracellular vesicles (EVs) had increased
amounts of the immunosuppressive cytokine TGFb1 and the lymphocyte activation inhibitor PD-L1.
Furthermore, these cells also showed enhanced resistance to antibody-dependent cell cytotoxicity (ADCC)
mediated by trastuzumab, indicating a role of NmU in enhancing immune evasion. All these features were
also found in HER2-targeted drug-resistant cells which we previously found to express higher levels of
NmU than their drug-sensitive counterparts. Interestingly, EVs from drug-resistant cells were able to
increase levels of TGFb1 in drug-sensitive cells. In our neo-adjuvant clinical trial, TGFb1 levels were
signiﬁcantly higher in EVs isolated from the serum of patients with HER2-overexpressing breast cancers
who went on to not respond to HER2-targeted drug treatment, compared with those who experienced
complete or partial response. Taken together, our results report a new mechanism-of-action for NmU in
HER2-overexpressing breast cancer that enhances resistance to the anti-tumor immune response.
Furthermore, EV levels of TGFb1 correlating with patients’ response versus resistance to HER2-targeted
drugs suggests a potential use of EV-TGFb1 as a minimally-invasive companion diagnostic for such
treatment in breast cancer.
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Introduction
Exosomes and/or ectosomes, collectively termed extracellu-
lar vesicles (EVs), are vesicles released from cells and are
typically considered to be miniature maps of their cell of
origin.1 Accumulating evidence from our own research and
that of others suggests that EVs are useful cargos of bio-
markers representing the cells from which they were
derived. They also appear to play important roles in cell-to-
cell communication and are implicated in tumor growth
and transferring drug-resistance.2,3
HER2 is overexpressed in »25% of breast cancers and is
associated with poorest prognosis.4 Therapies targeting HER2
(including monoclonal antibodies such as trastuzumab/Her-
ceptin and small molecules lapatinib and neratinib) have shown
encouraging results in the clinic. Unfortunately, not all HER2-
overexpressing tumors respond to these therapies and many
that initially respond later acquire resistance.5,6 Predictive com-
panion biomarkers for HER2-targeting drugs are thus urgently
needed for improved patient selection and enhanced patient
outcome. Ideally, such biomarkers should be extracellular so as
to be easily obtained through minimally invasive-techniques
from blood specimens. Of course, novel therapeutic strategies
to circumvent resistance are also badly needed.
It has been established that mechanisms that enhance drug-
resistance may also result in protection against cancer cell
destruction by the immune system.7 In a study representing
mesothelioma, leukemia and prostate cancers, tumor cell-
derived EVs were found to possess immunosuppressive proper-
ties and are proposed to participate in the transfer of these
traits to recipient cells.8 TGFb1 present in EVs was found to be
at least partly responsible for the immunosuppressive effects in
various cancer types.9,10 Whether EVs from HER2-targeted
drug resistant breast cancer cells have different immunosup-
pressive properties than those from drug sensitive cells has not
been investigated to date.
Neuromedin U (NmU) is a neuropeptide for which several
different functions have been ascribed. These include role(s) in
feeding, energy balance, smooth muscle contraction, stress
response, immune system activation and pain sensing.11,12 A
limited number of studies to date have associated NmU with
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cancer, with conﬂicting observations depending on the cancer
type. In breast cancer, we have shown that NmU expression is
increased in cells with innate- or acquired-resistance to HER2-
targeted therapies; furthermore, NmU overexpression was also
associated with increased migration, invasion and resistance to
anoikis.13 Assessing data from approximate 3,500 breast tumor
specimens, our work identiﬁed association between NmU
expression and poor survival outcome for breast cancer
patients; particularly those with HER2-overexpressing tumors.
Furthermore, our work also found an association between
NmU levels and the cell population with cancer stem cell
(CSC) phenotype (Martinez et al, unpublished results). Our in
vitro and in vivo NmU knock-down experiments pointed to a
role for NmU as a new therapeutic target to help circumvent
innate- and acquired- drug resistance, although the precise
mechanisms of action remained unexplained.
Here we show that HER2-targeted drug resistance in HER2-
positive breast cancer cells correlates with increased levels of
the immunosuppressive molecules TGFb1 and PD-L1 and
resistance to the anti-tumor immune response. Furthermore,
these molecules are carried by EVs, which are able to transfer
the traits of their cell of origin to drug-sensitive cells. EV-asso-
ciated TGFb1 levels also correlate with response to HER2-tar-
geted treatment in HER2-overexpressing breast cancer
patients, suggesting it could be used as a biomarker of response
to therapy. We have therefore revealed druggable targets –
TGFb1 and PD-L1 – to enhance the efﬁcacy of currently used
HER2-targeted therapies. Furthermore, we have also shown
that circulating levels of EV-associated TGFb1 have potential as
a predictive biomarker of patients’ treatment response.
Results
NmU overexpression increases TGFb1 levels
Our previous studies showed that increased expression of NmU
in tumor tissue is associated with poor prognosis in HER2-
overexpressing breast cancer patients13 and with expansion of
the CSC population (Martinez et al, unpublished results). As
has been shown previously,14 breast cancer cells with CSC phe-
notype secrete high levels of TGFb1. We then set out to deter-
mine whether NmU-overexpressing cells also showed increased
levels of TGFb1. As shown in Fig. 1A and B, TGFb1 levels were
increased in conditioned media from NmU-overexpressing
HCC1954 and SKBR3 cells. As expected, TGFb1 levels were
also increased in lapatinib-resistant HCC1954 cells compared
with their sensitive counterparts; the increase in TGFb1 levels
was not signiﬁcant for neratinib-resistant HCC1954 cells
(Fig. 1C). TGFb1 levels secreted by SKBR3 parent and resistant
cell variants were below the level of detection of the ELISA
(data not shown). Short-term treatment with NmU did not
result in release of TGFb1.
NmU overexpression increases cancer cell expression
of immunosuppressive mediators
We have previously reported that NmU overexpression in
HER2-positive breast cancer cells causes an enhancement in
drug resistance and a more aggressive phenotype, which is
commonly associated with resistance to the anti-tumor
immune response.15-17 Here our results show that NmU-over-
expressing cells secrete increased levels of TGFb1, which is a
well-known immunosuppressive cytokine. To evaluate the pos-
sibility that NmU confers cells the ability to evade destruction
by the immune system, expression of cell surface proteins
known to inhibit the immune response were assessed by ﬂow
cytometry in different cell variants. As shown in Fig. 1D and E,
overexpression of NmU in HER2-positive breast cancer cells
also increased the expression of the PD-L1 ligand, which has
been widely shown to suppress the anti-tumor immune
response; the levels of the immunosuppressive receptor CTLA-
4, however, were unchanged in both cell line variants (data not
shown). HER2-targeted drug-resistant HCC1954 cells also
showed increased levels of PD-L1 (Fig. 1F): however, no differ-
ences in PD-L1 expression were observed in neratinib-resistant
SKBR3 cells, while PD-L1 expression was actually decreased in
SKBR3 TR cells (Fig. 1G). Overall, our results show that over-
expression of NmU increases the levels of immunosuppressive
molecules TGFb1 and PD-L1 in HER2-positive breast cancer
cells; while the PD-L1 results differed in cells with acquired
resistance, depending on the drug in question and the cell line.
NmU-overexpressing cells are more resistant to ADCC
To analyze the functional consequences of NmU-overexpres-
sion, we performed antibody-dependent cell cytotoxicity
(ADCC) assays in different cell variants. NmU-overexpressing
HCC1954 cells were signiﬁcantly more resistant to ADCC
mediated by trastuzumab than control transfected counterparts
(Fig. 2A); similar results were obtained with NmU-overexpress-
ing SKBR3 cells, although the differences in this case were not
signiﬁcant (Fig. 2C). On the other hand, lapatinib- and nerati-
nib-resistant HCC1954 cell variants were also more resistant to
ADCC than their drug-sensitive counterparts (Fig. 2B): this
was not observed in SKBR3 drug-resistant cell variants. These
results suggest that, as well as enhancing resistance to HER2-
targeted drugs, overexpression of NmU increases the ability of
HER2-positive breast cancer cells to evade ADCC, which is one
of the main mechanisms of cancer cell death mediated by
trastuzumab.
EVs from NmU-overexpressing cells have more TGFb1
and PD-L1
EVs are known to transport cargo that is representative of their
cell of origin. Since NmU-overexpressing and HER2-targeted
drug-resistant cells displayed higher levels of TGFb1 and PD-
L1, we investigated whether this was also true of their derived
EVs. EVs were isolated from cell culture conditioned media by
ﬁltration and ultracentrifugation and characterized by speciﬁc
marker expression by immunoblotting and particle size analysis
(Suppl. Fig. 1) and also by transmission electron microscopy
(Suppl. Fig. 2). As expected, NmU levels were increased in EVs
derived from NmU-overexpressing and drug-resistant
HCC1954 cells, particularly in the case of neratinib-resistant
cells (Supp. Fig 3A and B). NmU levels were also increased in
EVs from neratinib-resistant EFM192A cells (Supp. Fig. 3C),
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but not in any of the drug-resistant SKBR3 cell variants (Suppl.
Fig. 3D).
Interestingly, TGFb1 levels were increased in intact
(unlysed) EVs from lapatinib, neratinib and trastuzumab-resis-
tant HCC1954, EFM192A and SKBR3 cells compared with
their sensitive counterparts (Fig. 3A, 3C and 3E); this effect
appears to be at least partly mediated by NmU, as EVs from
NmU-overexpressing HCC1954 cells also showed signiﬁcantly
increased TGFb1 levels compared with EVs from control-trans-
fected cells (Fig. 3A).
Furthermore, EVs from drug-resistant HCC1954 variants
also displayed increased levels of PD-L1 (Fig. 3B). This was not
observed for EVs from EFM192A and SKBR3 cell variants
(Fig. 3D and F); in fact, EVs from drug-resistant SKBR3 cell
variants displayed signiﬁcantly lower levels of PD-L1 compared
with EVs from their drug-sensitive counterparts, in agreement
with observations on their cells of origin. The increase in EV-
bound PD-L1 in HCC1954 cells did not appear to be mediated
by NmU, as EVs derived from NmU-overexpressing cells
showed similar levels of PD-L1 as those EVs derived from con-
trol transfected cells (Fig. 3B). Our results show that EVs from
HER2-targeted drug-resistant cells have higher content of
TGFb1, while changes in PD-L1 content are dependent on the
particular cell line.
EVs from drug-resistant cell variants can enhance TGFb1
secretion and PD-L1 expression in drug-sensitive cells
EVs have been shown to transfer traits from their cell of origin
to other, recipient cells. We then treated drug-sensitive
HCC1954, EFM192A and SKBR3 cells with EVs from their
drug-resistant variants and measured TGFb1 secretion and
Figure 1. Overexpression of NmU correlates with increased TGFb1 and PD-L1 levels. (A), (B), and (C), TGFb1 levels were determined by ELISA in serum-free conditioned
medium of HCC1954 and SKBR3 cell variants and expressed as pg TGFb1 per mg total cell protein. (D) and F, HCC1954 cell variants were stained with APC-labeled anti-
PD-L1, followed by FACS analysis in a FACSCanto II ﬂow cytometer. (E) and (G), Same as in (D) for SKBR3 cell variants. Results represent averaged replicates from at least 3
independent experiments. p < 0.05, p < 0.01, p < 0.001.
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PD-L1 expression. As shown in Fig. 4B, EVs from drug-
resistant HCC1954 cell variants induced an increase in TGFb1
secretion by HCC1954 Par cells. This increase did not appear
to be mediated by NmU (Fig. 4A). On the other hand, EVs
from drug-resistant EFM192A and SKBR3 cell variants did not
show the same effect (Fig. 4C and 4D). It should be noted that
TGFb1 secretion levels were much lower in these cells than in
HCC1954 cells.
Expression of PD-L1 was however increased by treatment
with EVs from drug-resistant variants from HCC1954 and
EFM192A cells (Fig. 5B, C and 5D), even when the EVs them-
selves did not appear to contain higher levels of PD-L1. In the
case of EVs from HCC1954 NR and SKBR3 cell variants the
increase was not signiﬁcant, but an upwards trend was
observed. This increase in PD-L1 expression could have been at
least partly mediated by NmU, as treatment with EVs from
NmU-overexpressing HCC1954 cells increased expression of
PD-L1 in HCC1954 Par cells (Fig. 5A). Overall, our results so
far show that EVs from HER2-targeted drug-resistant cell var-
iants can affect expression levels of TGFb1 and PD-L1 in recipi-
ent, drug-sensitive cells.
TGFb1 is a potential marker of response for HER2-positive
breast cancer treatment
Analysis of EVs from drug-resistant cell variants pointed to a
correlation between TGFb1 and resistance to HER2-targeted
drugs; this suggested a possible use of this molecule as a com-
panion diagnostics/predictive biomarker of response in breast
cancer patients with HER2-overexpressing tumors. To evaluate
this possibility, EVs were isolated from serum obtained from a
blinded study of patients before neo-adjuvant treatment
including trastuzumab with or without lapatinib. Isolated EVs
were characterized as described by immunoblotting and parti-
cle size analysis (Suppl. Fig. 4). TGFb1 and PD-L1 levels were
determined on intact EVs by ELISA. Patients were then fol-
lowed up and classiﬁed as complete responders (CR, n D 14),
partial responders (PR, n D 12) and non-responders (NR,
nD 4). As shown in Fig. 6A, EVs from NR patients showed sig-
niﬁcantly higher levels of TGFb1 than those of CR or PR
patients. Of note, no differences in EV quantities were observed
from specimens in the CR, PR or NR cohorts, indicating that
the higher amount of EV TGFb1 is not just a consequence of
increased numbers of EVs in patient serum. These results were
different from those obtained when measuring TGFb1 levels
directly in raw serum (Fig. 6B): while CR patients displayed sig-
niﬁcantly lower levels than either PR or NR patients, there were
no signiﬁcant differences between PR and NR patients, suggest-
ing that serum TGFb1 levels cannot distinguish between these 2
groups. No signiﬁcant differences were observed between CR,
PR and NR patient EVs regarding PD-L1 levels, although
increased quantities of EV-carried PD-L1 were found for those
who were classiﬁed as NR vs. PR vs. CR (Fig. 6C). These ﬁnd-
ings suggest that EV-carried TGFb1 –but not raw serum
TGFb1–may be able to identify those patients that would bene-
ﬁt from HER2-targeted treatment.
Discussion
In this study we show that NmU in HER2-positive breast can-
cer cells promotes evasion of the immune response, increasing
the expression of immunosuppressive molecules TGFb1 and
PD-L1 and functionally affecting ADCC, a key mechanism of
action of monoclonal antibodies used in the treatment of breast
Figure 2. Overexpression of NmU confers resistance to ADCC. Cells (A) and (C), HCC1954 cells, (B) and (D), SKBR3 cells) were seeded in a round bottom 96-well plate and
incubated with trastuzumab (100mg/ml). PBMCs were isolated from healthy donor blood by Ficoll gradient centrifugation and added on top of cells at the appropriate
ratios. Cells were incubated at 37C for a further 6h and cell lysis was then assessed by LDH release. (B) and (D), Same as in (A), but for SKBR3 cell variants. Averaged
results from technical triplicates from at least 2 independent experiments with PBMCs from different donors are shown. p < 0.05, p < 0.01, p < 0.001. [Note The
100% of cell lysis is calculated based on cancer cells alone and so sometimes the percentage of cell lysis following addition of PBMCs can be over 100% as some PBMCs
also die and release their LDH content into the medium].
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cancer. Interestingly, TGFb1 and PD-L1 are also detectable in
EVs from HER2-targeted drug-resistant cell variants, which
have been found to express high levels of NmU. EVs from these
cells can induce an increase in TGFb1 secretion in drug-sensi-
tive cells, promoting further immune evasion. Finally, EV-asso-
ciated TGFb1 levels also correlate with response to HER2-
targeted treatment in HER2-overexpressing breast cancer
patients, suggesting it could be used as a marker of response to
therapy.
EVs from cancer cells have been shown to carry immunosup-
pressive molecules such as FasL, TRAIL, TGFb1 and PD-L1,
9,18-19
and also to be involved in immunosuppression at several different
stages of the immune response, including T cell proliferation,
activation and apoptosis,9,20-21 regulatory T cell abundance and
function,23-25 NK cell function,22,26-27 dendritic cell maturation,28
induction of suppressive mesenchymal stem cells,29-30 and macro-
phage polarization.31 TGFb1 in EVs has been proposed to mediate
at least some of the immunosuppressive effects.9,10
Our previous work had shown an association between overex-
pression of NmU and an expansion of cells with CSC pheno-
type.32 The CSC phenotype is characterized by increased drug
resistance and also by enhanced immune evasion.33-35 In accor-
dance with this, as well as driving HER2-targeted drug resistance,
NmU overexpression was also associated with increased expres-
sion of TGFb1 and PD-L1, known inhibitors of the immune
response. Moreover, HER2-targeted drug-resistant cells were also
Figure 3. EVs from NmU-overexpressing and HER2-targeted drug-resistant variants show altered content of TGFb1 and PD-L1. (A), (C), and €, TGFb1 levels were deter-
mined by ELISA in intact (unlysed) EVs from HCC1954 (A), EFM192A (C) and SKBR3 (E) cell variants and expressed as pg TGFb1 per mg total EV protein. B, D, and F, PD-L1
levels were determined by ELISA in EVs from HCC1954 (B), EFM192A (D) and SKBR3 (F) cell variants and expressed as pg PD-L1 per mg total EV protein. Results represent
averaged replicates of at least 3 independent experiments. p < 0.05, p < 0.01, p < 0.001.
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shown to be more resistant to ADCC mediated by trastuzumab,
and this effect was at least partly mediated by NmU. These
results show that NmU-overexpressing cells are indeed more
capable of avoiding destruction by the immune system.
EVs have gathered a lot of interest in recent times due to the
understanding that they carry valuable information about their
cell of origin. Indeed, we found increased levels of TGFb1 in
EVs from drug-resistant cell variants, and this increase
appeared to be at least partly mediated by NmU. On the other
hand, PD-L1 levels were not consistently increased in EVs
from drug-resistant cell variants, similarly to what we observed
on their cells of origin. To our knowledge, this is the ﬁrst time
that EVs from drug-resistant cells have been shown to possess
enhanced immunosuppressive abilities compared with EVs
from drug-sensitive cells. Future studies where high levels of
NmU in resistant cells are knocked-down with siRNA or
shRNA to establish if this would reverse the increased vesicular
release of TGFb1/PD-L1 are now warranted. Their success may
lead to pre-clinical in vivo studies to establish the potential
therapeutic relevance of this approach.
Our previous work and that of others has shown that EVs
are able to transfer trends from their cell of origin to recipient
cells.1-3 Indeed, EVs from most of the drug-resistant cells tested
were able to increase the levels of secreted TGFb1 and cell sur-
face PD-L1 in parent, drug-sensitive cells.
It is noteworthy that HCC1954, SKBR3 and EFM192A -all
HER2-positive cell lines- were found to sometimes behave in
different ways under the same conditions. Possible contributing
reasons for this may include the fact that HCC1954 cells were
originally isolated from a primary breast tumor, while
EFM192A and SKBR3 cells were isolated from metastatic sites.
Also, their tumor type of origin is different i.e. HCC1954 cells
represent a ductal carcinoma, while EFM192A and SKBR3 cells
represent adenocarcinoma cells. The 3 cell lines also carry dif-
ferent driver mutations due to the diverse origin of their trans-
formation. The commonality of substantial importance here is
that they all represent HER2-overexpressing breast tumors.
Crucially, the fact that all 3 cell lines –despite tumor/patient-
to-patient differences– display increased TGFb1 levels on EVs
further highlights the relevance of this ﬁnding and how it
potentially could be applied to assessing patients whose HER2-
overexpressing breast tumors are different.
TGFb1 levels in EVs correlated particularly well with HER2-
targeted drug resistance displayed by their cells of origin. A
study in a small group of patients undergoing neo-adjuvant
treatment showed encouraging results, suggesting that high lev-
els of circulating EV TGFb1 may indicate that the tumor is
resistant to HER2-targeted therapy. Interestingly, the levels of
raw serum TGFb1 did not correlate as well with response to
treatment, indicating that there is an advantage in analyzing
EVs. If conﬁrmed, this would point to EV TGFb1 as a novel
biomarker of response to HER2-targeted therapy in HER2-
overexpressing breast cancer. However, these results should be
validated in a larger cohort.
Figure 4. Treatment with EVs from NmU-overexpressing and HER2-targeted drug-resistant variants enhances TGFb1 secretion. (A) and (B), HCC1954 Par cells were treated
with EVs from different HCC1954 cell variants (20 mg EV/1£ 105 cells) for 48 hr. Cell conditioned medium was then analyzed for TGFb1 content by ELISA, expressed as pg
TGFb1 per mg total cell protein. (C), Same as in (A) for EFM192A cells. (D), Same as in (A) for SKBR3 cells. Results represent averaged replicates of at least 3 independent
experiments. p < 0.01, p < 0.001.
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Figure 5. Treatment with EVs from NmU-overexpressing and HER2-targeted drug-resistant variants increases PD-L1 expression. (A) and (B), HCC1954 Par cells were
treated with EVs from different HCC1954 cell variants (20 mg EV/1 £ 105 cells) for 48 hr. PD-L1 surface staining was then analyzed by ﬂow cytometry. (C), Same as in
A for EFM192A cells. (D), Same as in (A) for SKBR3 cells. Results represent averaged replicates of at least 3 independent experiments and are expressed as fold difference
with respect to cells treated with EVs from parent cell variants, which is considered to be equal to 1. p < 0.05.
Figure 6. EV TGFb1 levels correlate with response to HER2-targeted therapy in HER2-overexpressing breast cancer patients. EVs were isolated from 250 ml patients’ sera
by serial ultracentrifugation. (A), TGFb1 was detected on intact EVs isolated from patient serum by ELISA. Values are expressed as pg TGFb1 per ml of serum. (B), TGFb1
was detected in patients’ sera by ELISA. Values are expressed as pg TGFb1 per ml of serum. C, PD-L1 was detected on intact EVs by ELISA. Values are expressed as pg PD-
L1 per mg total EV protein. p  0.05, p < 0.01.
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It may also be interesting, in future studies, to consider the
multiple forms of TGFb1. Our results represent analysis, by
ELISA, of the mature form of TGFb1. However, using an immu-
noblotting approach, Graner et al.36 reported that EVs from gli-
oma patient sera have multiple forms of TGFb1 i.e., forms of
pro-peptide, LAP, dimer -presumably the active form- and
monomer. More recently and also using immunoblotting, multi-
ple TGFb1 forms have been shown on EVs from AML patient
plasma (albeit in very small numbers of specimens) and the EVs
with more of the “active/mature” form of TGFb1 correlated with
greater capacity to suppress NK cell activity.37 For our studies
reported here, we selected the approach (ELISA) that we took
because we are not conﬁdent that immunoblotting techniques
would easily translate into routine clinical utility for a blood-
based biomarker (e.g. to predict response to therapy for patients
enrolling in a clinical trial), while ELISAs are routinely used in
clinics and hospital laboratories. However, undoubtedly using
the less quantitative immunoblotting approach could help gener-
ate new scientiﬁc knowledge -which is also fundamentally
important- that could complement the quantitative ELISA data.
NmU is an attractive target for HER2-overexpressing breast
cancer, but the multiple physiologic roles it plays would make
it difﬁcult to alter its function without side-effects. The identiﬁ-
cation of downstream druggable mediators of its effects such as
TGFb1 and PD-L1 suggest novel ways in which NmU function
can be targeted for the treatment of HER2-overexpressing
breast cancer. Combination with therapies that block these
downstream effectors of NmU could then add value to cur-
rently approved HER2-targeted therapies.
Materials and methods
Cell culture and treatments
HCC1954, SKBR3 and EFM192A cells, obtained from ATCC,
were cultured in RPMI-1640 (Sigma-Aldrich, Ireland) with
10% FCS (PAA Laboratories, UK) and 1% L-glutamine (Sigma-
Aldrich, Ireland). Our HCC1954 and SKBR3 NmU and mock-
transfected cells have been described previously,3 as have lapati-
nib-resistant (HCC1954 LR), neratinib-resistant (HCC1954
NR, SKBR3 NR and EFM192A NR) and trastuzumab-resistant
(SKBR3 TR) variants.13,38 For short-term treatment with NmU
peptide, cells (1 £ 105 cells) were seeded in a 24-well plate,
allowed to attach overnight, fed with serum-free medium and
subsequently treated with 1–10 mmol/L of NmU-25
(Bachem AG, Switzerland) for 1 hour. Cell lines are authenti-
cated by short tandem repeat proﬁling (at least every 2 years)
and tested for Mycoplasma using qPCR methods (quarterly).
All experiments are performed within 10 passages of thawing
and biologic replicate experiments are performed on consecu-
tive passages numbers of cells. Lapatinib and neratinib were
purchased from Sequoia Chemicals Ltd (UK); trastuzumab
(Herceptin) was obtained from St. James’ Hospital Pharmacy,
TCD.
Immunoblotting
Total cellular proteins (10mg for extracellular vesicles, 30–
40 mg for cell lysates, depending on the speciﬁc protein
abundance but constant for any given protein) were resolved
on 10% SDS-PAGE and transferred to polyvinylidene diﬂuor-
ide membranes (Millipore, Ireland). Primary antibodies used
included Grp94 (1:1000, Abcam, UK), PDC6I/Alix (1:1000,
Abcam, UK) and CD81 (1:200, Abcam, UK). Membranes were
incubated with appropriate horseradish peroxidase-conjugated
secondary antibodies (Cell Signaling Technology, Netherlands)
and proteins were visualized by chemiluminescence (Millipore,
Ireland). Detection was performed with a Chemidoc exposure
system (Bio-Rad Laboratories, UK).
Nanoparticle tracking analysis
Analysis was performed on all EVs with the NTA NS500 sys-
tem (NanoSight, Amesbury, UK) to determine particle size
based on Brownian motion. EV samples were diluted 1:100 in
PBS and injected into the NTA system, which obtained 6 60
second videos of the particles in motion. Videos were then ana-
lyzed with the NTA software to determine particle size.
ELISA
ELISA kits for human TGFb1, PD-L1 (R&D Systems, UK) and
NmU (Peninsula Laboratories, CA) were used according to the
manufacturer’s instructions. For analysis of conditioned media,
HCC1954, SKBR3 and EFM192A cell variants were seeded at 1
£ 105 cells/well in a 24-well plate and left to attach overnight.
The following day, cells were washed and fed with serum-free
media and incubated for a further 72hr. Supernatant was then
collected and analyzed immediately or stored at ¡80C until
analysis. Results were normalized by total cell protein con-
tained in the well. 10mg of protein from lysed or intact EVs, as
stated, were tested per well.
Flow cytometry
HCC1954 and SKBR3 cell variants (1 £ 105/well) were seeded
in a 6-well plate and allowed to attach overnight. They were
then trypsinised, blocked with 10% FCS in PBS and stained
with APC-conjugated anti-CD24 (1:75 dilution, eBiosciences,
UK) and FITC-conjugated anti-CD44 (1:800 for HCC1954,
1:400 for SKBR3, eBiosciences, UK) or APC-conjugated anti-
PD-L1 antibody (1:800 for HCC1954, 1:400 for SKBR3, eBio-
sciences, UK) for 30 min at 4C. For EV treatment, cells were
seeded at 0.5 £ 105 (HCC1954) or 1 £ 105 (SKBR3 and
EFM192A) cells/well in a 24-well plate and allowed to attach
overnight. The following day, cells were washed with serum-
free media, fed with media supplemented with extracellular
vesicle (EV)-depleted-FBS and treated with EVs for a further
48 hr before staining as above. Staining was assessed in a FACS-
Canto II ﬂow cytometer, followed by analysis with BD FACS-
Diva software.
Antibody-dependent cell cytotoxicity (ADCC) assay
HCC1954 cell variants were seeded at 1 £ 104 cells/well in a
round bottom 96-well plate and incubated with trastuzumab
(100mg/ml) for 30 min at 37C. Whole blood was obtained
from healthy donors in accordance with a protocol approved
e1362530-8 V. G. MARTINEZ ET AL.
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by the Research Ethics Committee at Trinity College Dublin.
PBMCs were isolated from blood by Ficoll gradient centrifuga-
tion (Histopaque, Sigma-Aldrich, UK) and added on top of
cells at the appropriate ratios. Cells were incubated at 37C for
a further 6 h and cell lysis was then assessed by LDH release
(CytoTox-ONETM Homogeneous Membrane Integrity Assay,
Promega, UK).
Extracellular vesicle isolation from conditioned media
HCC1954, SKBR3 and EFM192A cell variants were seeded (1.7
£ 107 cells/ﬂask in a 15 ml volume) in CELLine Adhere 1000
ﬂasks (Integra Biosciences AG, Switzerland) in complete
medium containing 10% extracellular vesicle (EV)-depleted-
FBS, 2 mM L-Glutamine, 1% penicillin/streptomycin (Sigma–
Aldrich, Ireland), and grown as described previously.39 Condi-
tioned media (CM) was collected every 7 d and processed for
EV isolation. In brief, CM was centrifuged at 400 g for 10 min
and 2000 g for 15 min to eliminate cells and cell debris, then ﬁl-
tered through a 0.45 mm pore ﬁlter and subsequently ultracen-
trifuged at 110,000 g for 75 min at 4C, using an SW32.Ti
swing bucket rotor. EV pellets were washed in PBS and ultra-
centrifugation repeated. EVs were then assessed using the BCA
assay (Bio-Rad Laboratories, UK) and further characterized by
nanoparticle tracking analysis (NanoSight) and immunoblot-
ting for positive and negative markers.40
Extracellular vesicle isolation from patients’ specimens
Serum specimens were obtained from patients accrued to the
All Cooperative Oncology Research Group (ICORG/Cancer
Trials Ireland) translational trial NCT01485926. The procure-
ment and analysis of these specimens was approved by the
Ethics Committees of the associated hospitals and in accor-
dance with the Helsinki Declaration of 1975. Specimens were
taken before neo-adjuvant treatment that included trastuzumab
with or without lapatinib. Following 6 cycles of treatment,
response was assessed in accordance with ICORG guidelines,
and deﬁned as pathological complete response (CR) by the
absence of invasive carcinoma in the breast and lymph nodes.
Pathological partial response (PR) was deﬁned as a decrease in
either or both the tumor or lymph nodes compared with the
pre-treatment tumor or lymph nodes, while having no increase
in either the tumor or lymph nodes, while no pathological
response (NR) was deﬁned as no apparent change in either the
tumor or lymph nodes compared with the clinical (pre-treat-
ment) assignment or an increase in the tumor or lymph nodes
at the time of post-treatment pathologic evaluation. Patient
information (age, tumor score, lymph node status, metastasis
status and overall staging) can be found in Supplementary
Table 1. EVs were isolated from 250ml serum diluted in 8 ml
PBS, ﬁltered through 0.2mm syringe ﬁlter and ultracentrifuged
at 110,000 g for 75 min at 4C, using a 70.1 Ti ﬁxed angle rotor.
EV pellets were washed in PBS and ultracentrifugation
repeated. EVs were then assessed using the BCA assay (Bio-
Rad Laboratories, UK), nanoparticle tracking analysis (Nano-
Sight), immunoblotting for positive and negative markers and
transmission electron microscopy (TEM) as described
previously.11,12 EV pellets re-suspended in 200ml PBS were
stored at ¡80C until analysis.
Statistical analysis
One-way ANOVA followed by Tukey’s post-test was used for
analysis of multiple comparison groups. Two-tailed Student’s
unpaired t-test was used to compare 2 groups. Statistical analy-
ses were performed using GraphPad Prism 5 (GraphPad Soft-
ware, Inc., CA). Results are expressed as mean of a minimum
of 3 independent experiments (except when noted otherwise)
§ SEM. Statistical signiﬁcance was set at p < 0.05; p < 0.01;
p < 0.001.
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